Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP503 (NBTXR3) with Chemoradiotherapy in Head and Neck Cancer
NCT02901483Phase 2Terminated
- Sponsor
- PharmaEngine, Inc.
- Start
- Oct 2016
- Primary completion
- Aug 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NBTXR3 in head and neck squamous cell carcinoma (HNSCC), sponsored by PharmaEngine, Inc. Primary endpoints: Dose Limiting Toxicity, Rate of Locoregional Control at 1 year and 1 more. Started Oct 2016; status: terminated.
02
Drugs
NBTXR3
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02901483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901483.